JW THERAP-B Soars Over 5% to Reach HK$3.73 in 2023.

March 18, 2023

Categories: BiotechnologyTags: , , Views: 13

Trending News ☀️

JW ($SEHK:02126) THERAP-B, a leading healthcare provider in Hong Kong, has seen its share price soar over 5% to reach HK$3.73 in 2023. Investors are reassured by the company’s financial strength and long-term growth potential as it continues to expand its product and service offerings. JW THERAP-B is renowned for its innovative approach to delivering healthcare services. The company has invested heavily in research and development of new treatments, technologies, and therapies to improve patient outcomes, while also introducing new services such as telemedicine, health apps, and more. These investments have enabled JW THERAP-B to deliver value to customers and maintain its competitive edge.

The company’s strong financials have also contributed to the rally in its share price. This suggests that the company is well-positioned for long-term growth, making it an attractive prospect for investors. Given its impressive performance so far, it appears that JW THERAP-B is on track to continue its upward trend. With its strong financials, promising product and service offerings, and innovative approach to healthcare, the company looks set to maintain its current trajectory.

Stock Price

The news coverage of JW THERAP-B has been mostly positive lately, and on Friday, their stock soared higher than ever. The stock opened at HK$3.6 and closed at HK$3.8, which is a 6.8% increase from the prior closing price of HK$3.5. This marks a new all-time high for the company in 2023, reaching HK$3.73. The stock has gained an impressive 5% since the beginning of the year, and investors are confident that the company will continue to achieve growth in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Jw. More…

    Total Revenues Net Income Net Margin
    96.8 -850.89 -881.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Jw. More…

    Operations Investing Financing
    -650.8 -127.17 -20.9
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Jw. More…

    Total Assets Total Liabilities Book Value Per Share
    2.9k 293.03 6.34
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Jw are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -748.3% -19.6% -18.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have conducted a thorough analysis of JW‘s financials. Our Risk Rating system has determined that JW is a medium risk investment in terms of financial and business aspects. We have identified particular areas of risk that should be taken into consideration when making an investment decision. In particular, our analysis of the balance sheet and cashflow statement have revealed two potential risk warnings. To access these warnings and gain a better understanding of the associated risks, we invite you to register with us. With GoodWhale, you can trust that you are getting accurate and up-to-date information about the financials of any company you are considering investing in. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Founded in 2014, the company has been a leader in the development of next-generation cancer therapies. JW (Cayman) Therapeutics Co Ltd faces competition from other biotechnology companies such as Elicera Therapeutics AB, Onconova Therapeutics Inc, and MAIA Biotechnology Inc who are all striving to develop breakthrough cancer treatments.

    – Elicera Therapeutics AB ($BER:8E8)

    Elicera Therapeutics AB is a biopharmaceutical company focused on the development of novel therapies for the treatment of cancer. The company’s market cap, as of 2022, is 6.91M. This is an indication of the company’s financial health and performance in the market. The company also has a negative Return on Equity (ROE) of 27.25%, which is lower than the industry average. This indicates that the company is not able to generate profits from its operations and has been inefficient in its use of equity capital. Despite this, the company continues to invest in its research and development activities to bring new and innovative treatments to the market.

    – Onconova Therapeutics Inc ($NASDAQ:ONTX)

    Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company which focuses on the development of novel small molecule drugs to treat cancer. The company has a market capitalization of 13.86M as of 2022, which indicates its small size in the industry. Onconova’s Return on Equity (ROE) is -30.71%, which is not ideal as it indicates that the company is not generating enough profits from its invested capital. This poor performance is likely due to the company’s current focus on developing and commercializing novel small molecule drugs, which often take years and require substantial investments before they can generate a return.

    – MAIA Biotechnology Inc ($NYSEAM:MAIA)

    MAIA Biotechnology Inc is a biotechnology company that develops and commercializes innovative technology for the diagnosis and treatment of cancer. The company has a market capitalization of 36.23M as of 2022. This indicates that the total market value of all of its outstanding shares is 36.23 million. In addition, MAIA Biotechnology Inc has a negative Return on Equity (ROE) of -89.15%. This suggests that the company is not generating enough profits to cover the cost of its equity, which is likely to be a sign of financial distress.


    JW THERAP-B has seen tremendous growth in their stock price. This surge has been driven largely by positive news coverage surrounding the company. On the day of the news, the stock price experienced a notable uptick. To invest in JW THERAP-B, investors should consider the company’s strengths and weaknesses, as well as its overall future prospects. Analysts suggest that JW is a good option due to its strong balance sheet and experience in the industry. Additionally, their high-value product offerings make them an attractive choice for investors looking for long-term growth.

    However, investors should also be aware of risks such as a weak macroeconomic environment, competition, and changing customer needs. All this must be taken into account when deciding whether to invest in JW THERAP-B.

    Recent Posts

    Leave a Comment